Skip to main content
. Author manuscript; available in PMC: 2026 Jul 1.
Published in final edited form as: Cancer Treat Res Commun. 2023 Dec 20;43:100784. doi: 10.1016/j.ctarc.2023.100784

Table 2.

Participant demographic and clinical characteristics (n= 30).

Age (years) Mean
54.6
Frequency
SD
9.09
Percentage
Race
White/Caucasian 23 76.7
Black/African American 6 20.0
Asian 1 3.33
Ethnicity
Not Hispanic/Latino 17 56.7
Hispanic/Latino 13 43.3
Marital Status
Married 20 66.7
Single 4 13.3
Divorced 4 13.3
Widowed 2 6.67
Employment Status
Employed outside the home, full-time 18 60.0
Retired 6 20.0
Homemaker 3 10.0
Employed outside the home, part-time 2 6.67
Disabled due to illness 1 3.33
Education (years)
16 (college graduate) 13 43.3
14 8 26.7
17 (graduate or professional training) 4 13.3
12 (high school diploma) 3 1.00
13 1 3.33
15 1 3.33
Risk assessment
Family history of breast cancer 19 63.3
Previous hormone use 13 43.3
Genetic predisposition 3 10.0
Dense breast 15 50.0
History of DCIS 9 30.0
History of LCIS 5 16.7
History of atypical hyperplasia 15 50.0
History of Breast Surgery
Lumpectomy 14 46.7
Simple Mastectomy 1 3.3
Current Endocrine/Hormonal Therapy
Tamoxifen (Nolvadex, Soltamox) 20 66.7
Raloxifene (Evista) 5 16.7
Anastrozole (Arimidex) 4 13.3
Exemestane (Aromasin) 1 3.33